TCGA-MP-A4TJ-01A-51R-A262-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.580
- ALLOGRAFT_REJECTION+0.560
- TNFA_SIGNALING_VIA_NFKB+0.540
- INTERFERON_ALPHA_RESPONSE+0.530
- IL6_JAK_STAT3_SIGNALING+0.510
- INFLAMMATORY_RESPONSE+0.480
- COMPLEMENT+0.340
- IL2_STAT5_SIGNALING+0.310
- KRAS_SIGNALING_UP+0.300
- UV_RESPONSE_DN+0.210
Top 10 suppressed
- MYC_TARGETS_V1-0.540
- MYC_TARGETS_V2-0.530
- E2F_TARGETS-0.520
- OXIDATIVE_PHOSPHORYLATION-0.490
- G2M_CHECKPOINT-0.470
- GLYCOLYSIS-0.370
- ADIPOGENESIS-0.340
- DNA_REPAIR-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- MTORC1_SIGNALING-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.925 |
| 2 | DRR168552 | — | — | 0.921 |
| 3 | d24acd56-d148-487c-8d44-b303a68eb9d2 | — | — | 0.908 |
| 4 | SRR2932841 | — | — | 0.901 |
| 5 | TCGA-55-6971-01A-11R-1949-07 | — | cohortMD2 | 0.900 |
| 6 | 6dfa748c-af43-469f-a98b-8472a4132739 | — | — | 0.899 |
| 7 | DRR168577 | — | — | 0.898 |
| 8 | DRR168509 | — | — | 0.897 |
| 9 | 20030005.Her2HRpos | — | A | 0.891 |
| 10 | AUR-AE6X-TTP1-A-1-0-R-A741-41 | — | D | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.540 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.020 | Inavolisib | — uncovered |